Novel SARS-CoV-2 allosteric inhibitors that destabilize the Main Protease Mpro dimer
Beatrice Mercorelli, Alessandro Bazzacco, Michela Eleuteri, Samuele Di Cristofano, Jenny Desantis, Alessandro Paciaroni, María Grazia Ortore, Sara Tuci, Francesco Spinozzi, Domenico Raimondo, Laura Goracci, Gabriele Cruciani, Arianna Loregian · International Journal of Biological Macromolecules · 2025
SARS-CoV-2 Main protease (M pro ) is the most explored coronavirus antiviral target, being most antivirals approved or under development protease inhibitors. M pro is active as a dimer and the molecular details of its maturation are poorly understood. Some compounds that crystallize at the dimerization interface rather than at the catalytic pocket have been proposed as allosteric inhibitors. Here, we characterize a series of novel compounds starting from a scaffold identified by an in silico screening for M pro catalytic pocket. Several compounds showed anti-SARS-CoV-2 activity in infected cells, but they did not inhibit M pro in vitro . Time-of-addition studies pointed to a stage compatible with M pro targeting. Molecular modelling studies suggested that compounds 1 and 11 bind M pro similarly to the allosteric inhibitor AT7519 . Small-angle X-ray scattering studies revealed that 1 and 11 strongly shift M pro equilibrium to the monomeric form, while the allosteric inhibitor pelitinib and the catalytic inhibitors nirmatrelvir and GC376 stabilize the dimer. Compounds 1 and 11 inhibited M pro proteolytic activity in SARS-CoV-2 infected cells acting as allosteric inhibitors that stabilize the monomeric form. In conclusion, we validated an allosteric site in M pro that could be exploited for the development of effective anti-SARS-CoV-2 antivirals targeting M pro with a novel mechanism.